Monday’s FDA approval makes Filspari the first therapy specifically indicated for FSGS, a condition that represents a $1 ...
Despite encountering a legal roadblock last month in his effort to rework the U.S. vaccine infrastructure, HHS secretary ...
As geopolitics bring reshoring interest to a fever pitch, the United States Pharmacopeia (USP) is adding to the impetus for ...
Novartis is making further workforce reductions at its U.S. headquarters in New Jersey, planning to eliminate 114 positions ...
Charles River Laboratories has backed an American Heart Association (AHA) campaign, joining forces with the nonprofit on ...
Envision Pharma Group has hired clinical research veteran Nick Jones as president of its Envision Medical Communications (EMC ...
Fierce Biotech has released its annual ranking of the top 10 pharma R&D budgets of 2025—offering a clear look at which ...
Amneal and BioCorRx have earned the ire of the FDA’s Office of Prescription Drug Promotion (OPDP), with both being hit by ...
Takeda ended its neurogenerative disease partnership with Denali Therapeutics. Merck & Co. and Zhifei have scrapped a minimum ...
Novartis is launching a three-front push to close healthcare gaps in heart disease and cancer, expanding initiatives with the ...
Most biopharma brands have more approved content than ever before. Yet HCP and patient engagement haven’t kept pace. | Omnichannel isn’t a content problem. It’s an access problem. See how compliant AI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results